Otsuka- Lundbeck’s Schizophrenia Drug Abilify Maintena Gets Health Canada Clearance

Otsuka and Lundbeck has received approval from Health Canada to use its intramuscular (IM) once-monthly injectable formulation 'Abilify Maintena' for the maintenance treatment of schizophrenia in stabilized adult patients. Abilify Maintena will be the first commercialized product in Canada from the global Otsuka- Lundbeck alliance, which is focused on developing Central Nervous System (CNS) therapies worldwide. It helps in reducing the risk of relapse relative to placebo over the long-term and provides effective treatment of schizophrenia. This was reported by PBR on February 14, 2014. Contact information: Rose Weldon, Associate Director, Communications, Otsuka America Pharmaceutical, Inc., 2440 Research . . .